Efficacy of intranasal vaccination with a multivalent vaccine containing temperature-sensitive modified-live bovine herpesvirus type 1 for protection of seronegative and seropositive calves against respiratory disease

Suman M. Mahan Veterinary Medicine Research and Development, Zoetis Inc, 333 Portage St, Kalamazoo, MI 49009.

Search for other papers by Suman M. Mahan in
Current site
Google Scholar
PubMed
Close
 BVM, PhD
,
Brian Sobecki Veterinary Medicine Research and Development, Zoetis Inc, 333 Portage St, Kalamazoo, MI 49009.

Search for other papers by Brian Sobecki in
Current site
Google Scholar
PubMed
Close
 BS
,
John Johnson Veterinary Medicine Research and Development, Zoetis Inc, 333 Portage St, Kalamazoo, MI 49009.

Search for other papers by John Johnson in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Nancee L. Oien Veterinary Medicine Research and Development, Zoetis Inc, 333 Portage St, Kalamazoo, MI 49009.

Search for other papers by Nancee L. Oien in
Current site
Google Scholar
PubMed
Close
 PhD
,
Todd R. Meinert Veterinary Medicine Research and Development, Zoetis Inc, 333 Portage St, Kalamazoo, MI 49009.

Search for other papers by Todd R. Meinert in
Current site
Google Scholar
PubMed
Close
 PhD
,
Sarah Verhelle Veterinary Medicine Research and Development, Zoetis Inc, 333 Portage St, Kalamazoo, MI 49009.

Search for other papers by Sarah Verhelle in
Current site
Google Scholar
PubMed
Close
 BS
,
Sally J. Mattern Veterinary Medicine Research and Development, Zoetis Inc, 333 Portage St, Kalamazoo, MI 49009.

Search for other papers by Sally J. Mattern in
Current site
Google Scholar
PubMed
Close
 BS
,
Terry L. Bowersock Veterinary Medicine Research and Development, Zoetis Inc, 333 Portage St, Kalamazoo, MI 49009.

Search for other papers by Terry L. Bowersock in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
, and
Randy D. Leyh Veterinary Medicine Research and Development, Zoetis Inc, 333 Portage St, Kalamazoo, MI 49009.

Search for other papers by Randy D. Leyh in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

OBJECTIVE To evaluate efficacy and duration of immunity of the bovine herpesvirus type 1 (BHV-1) fraction of a trivalent vaccine also containing parainfluenza virus-3 and bovine respiratory syncytial virus fractions administered intranasally (IN) for protection of calves against infectious bovine rhinotracheitis (IBR).

DESIGN Controlled challenge study.

ANIMALS 120 dairy calves (3 to 8 days old) seronegative for antibody against BHV-1 (experiments 1 and 2) or seropositive for maternally derived antibody against BHV-1 (experiment 3).

PROCEDURES In 3 separate experiments, calves were vaccinated IN via 2 nostrils (experiment 1) or 1 nostril (experiments 2 and 3) with a vaccine containing or not containing a BHV-1 fraction. For seronegative calves, the test vaccine contained a minimum immunizing dose of BHV-1; for seropositive calves, it contained a commercial dose of BHV-1. Calves were challenged IN with virulent BHV-1 on day 28 or 193 (seronegative calves) or day 105 (seropositive calves) after vaccination to evaluate vaccine efficacy. Frequency and duration of clinical signs, rectal temperatures, virus shedding, and serologic responses were compared between treatment groups within experiments.

RESULTS In all experiments, BHV-1 vaccinated calves had lower frequencies or shorter durations of clinical signs of IBR than did control calves. Following viral challenge, peak rectal temperatures and degrees of virus shedding were lower and serologic responses were higher in vaccinated versus control calves.

CONCLUSIONS AND CLINICAL RELEVANCE IN vaccination against BHV-1 protected all calves against clinical IBR disease, regardless of serologic status at the time of vaccination, and suppressed virus shedding. A single dose of this IN vaccine has the potential to protect seronegative calves for at least 193 days and override maternally derived antibody to protect seropositive calves for at least 105 days.

Abstract

OBJECTIVE To evaluate efficacy and duration of immunity of the bovine herpesvirus type 1 (BHV-1) fraction of a trivalent vaccine also containing parainfluenza virus-3 and bovine respiratory syncytial virus fractions administered intranasally (IN) for protection of calves against infectious bovine rhinotracheitis (IBR).

DESIGN Controlled challenge study.

ANIMALS 120 dairy calves (3 to 8 days old) seronegative for antibody against BHV-1 (experiments 1 and 2) or seropositive for maternally derived antibody against BHV-1 (experiment 3).

PROCEDURES In 3 separate experiments, calves were vaccinated IN via 2 nostrils (experiment 1) or 1 nostril (experiments 2 and 3) with a vaccine containing or not containing a BHV-1 fraction. For seronegative calves, the test vaccine contained a minimum immunizing dose of BHV-1; for seropositive calves, it contained a commercial dose of BHV-1. Calves were challenged IN with virulent BHV-1 on day 28 or 193 (seronegative calves) or day 105 (seropositive calves) after vaccination to evaluate vaccine efficacy. Frequency and duration of clinical signs, rectal temperatures, virus shedding, and serologic responses were compared between treatment groups within experiments.

RESULTS In all experiments, BHV-1 vaccinated calves had lower frequencies or shorter durations of clinical signs of IBR than did control calves. Following viral challenge, peak rectal temperatures and degrees of virus shedding were lower and serologic responses were higher in vaccinated versus control calves.

CONCLUSIONS AND CLINICAL RELEVANCE IN vaccination against BHV-1 protected all calves against clinical IBR disease, regardless of serologic status at the time of vaccination, and suppressed virus shedding. A single dose of this IN vaccine has the potential to protect seronegative calves for at least 193 days and override maternally derived antibody to protect seropositive calves for at least 105 days.

All Time Past Year Past 30 Days
Abstract Views 702 0 0
Full Text Views 1397 1084 36
PDF Downloads 498 182 39
Advertisement